<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01956786</url>
  </required_header>
  <id_info>
    <org_study_id>Ausa-Amlodipine B</org_study_id>
    <nct_id>NCT01956786</nct_id>
  </id_info>
  <brief_title>Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine</brief_title>
  <official_title>Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine in Patients With Mild to Moderate Hypertension, Hyperhomocysteinemia and Angiotension-Converting Enzyme Inhibitor Intolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Ausa Pharmed Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenzhen Ausa Pharmed Co.,Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of Amlodipine-Folic Acid Tablets on reduction of blood pressure and&#xD;
      plasma total homocysteine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Traditional risk factors are estimated to account for only part of cardiovascular disease&#xD;
      (CVD)risk. Non-traditional risk factors such as increased homocysteine concentrations are&#xD;
      believed to be causally related to CVD. The interactive effect between hypertension and&#xD;
      hyperhomocysteinemia on the risk of CVD has received great attention.&#xD;
      Methylenetetrahydrofolate reductase (MTHFR)was the main regulatory enzymes for homocysteine&#xD;
      metabolism. MTHFR converts 5,10-methylene-THF into 5-methyl-THF. Polymorphism of MTHFR C677T&#xD;
      leads to a reduction in enzyme activity, which may lead to an increased concentration of&#xD;
      plasma homocysteine and lower levels of serum folate, particularly in those with low folate&#xD;
      intake. Enalapril Maleate-Folate Tablets, known to reduce both blood pressure and serum&#xD;
      homocysteine and thereby preventing stroke, was found to have adverse events, such as cough,&#xD;
      called ACEI-intolerance in some patients.&#xD;
&#xD;
      In the present study, we sought to assess:(1)the efficacy and safety of Amlodipine-Folic Acid&#xD;
      Tablets in lowing blood pressure and homocysteine in patients with mild to moderate&#xD;
      hypertension, hyperhomocysteinemia (hcy≥10μmol/L)and ACEI intolerance;(2)whether the blood&#xD;
      pressure and homocysteine-lowing efficacy of Amlodipine-Folic Acid Tablets can be modified by&#xD;
      individual MTHFR C677T polymorphisms.&#xD;
&#xD;
      In all, about 540 patients with mild to moderate hypertension, hyperhomocysteinemia and ACEI&#xD;
      intolerance will be enrolled in this trial. Eligible subjects are randomly and double-blindly&#xD;
      assigned to one of the three treatment groups:1)amlodipine tablet(5mg,control&#xD;
      group);2)amlodipine-folic acid tablet(5mg amlodipine combined with 0.4mg of folic acid,low FA&#xD;
      group);or 3)amlodipine-folic acid tablet (5mg amlodipine combined with 0.8mg of folic&#xD;
      acid,high FA group),once daily for 8 weeks.&#xD;
&#xD;
      The allocation of participants was programmed by an independent statistical coordinating&#xD;
      center,encrypted,and sent to each study center.Tablet containers were labeled only with the&#xD;
      name of the trial and the allocated concealment number.The participants,care partners,and all&#xD;
      staff directly involved in the trial were blinded to interventions during the period of the&#xD;
      trial.&#xD;
&#xD;
      Demographic and clinical information were obtained at baseline. Blood pressure was examined&#xD;
      at baseline and every two weeks for a total period of 8 weeks. Blood homocysteine and folate&#xD;
      concentrations were examined at baseline and at 4th、8th weeks of the trial. MTHFR C677T&#xD;
      genotypes were determined for each study subject.&#xD;
&#xD;
      All analyses will be performed according to the principle of intention to treat.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined effective rate of blood pressure and plasma homocysteine reduction</measure>
    <time_frame>Blood pressure was examined at baseline and every 2 weeks for a total period of 8 weeks.Blood homocysteine concentrations were measured at baseline and at 4th and 8th week of the trial.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure reduction or plasma homocysteine reduction</measure>
    <time_frame>Blood pressure was examined at baseline and every 2 weeks of a total period of 8 weeks. Blood homocysteine concentrations was examined at baseline and at 4th and 8th week of the trial.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">540</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5mg amlodipine,once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine-FA tablet,low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg amlodipine combined with 0.4mg of folic acid (FA),once daily for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine-FA tablet,high dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg amlodipine combined with 0.8mg of folic acid (FA),once daily for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine-FA tablet,low dose group</intervention_name>
    <description>5mg amlodipine combined with 0.4mg folic acid,once daily (Low-dose group)</description>
    <arm_group_label>Amlodipine-FA tablet,low dose group</arm_group_label>
    <other_name>low dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine-FA tablet,high dose group</intervention_name>
    <description>5mg amlodipine combined with 0.8mg folic acid,once daily (High-dose group)</description>
    <arm_group_label>Amlodipine-FA tablet,high dose group</arm_group_label>
    <other_name>high dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>5mg amlodipine,once daily</description>
    <arm_group_label>Amlodipine</arm_group_label>
    <other_name>control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18-75 years;&#xD;
&#xD;
          2. Sedentary systolic blood pressure between 140 mmHg and 180 mmHg, and/or sedentary&#xD;
             diastolic blood pressure between 90 mmHg and 110 mmHg;&#xD;
&#xD;
          3. Plasma homocysteine ≥ 10μmol/L;&#xD;
&#xD;
          4. ACEI-intolerance&#xD;
&#xD;
          5. Signed the written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant women or women within lactation period;&#xD;
&#xD;
          2. Hypersensitive to Calcium Channel Blocker (CCB) or folic acid;&#xD;
&#xD;
          3. Easily hypersensitiveness;&#xD;
&#xD;
          4. Diagnosed secondary hypertension or skeptical secondary hypertension;&#xD;
&#xD;
          5. Severe hypertension (sedentary systolic blood pressure greater than or equal to 180&#xD;
             mmHg and/or sedentary diastolic blood pressure greater than or equal to 110 mmHg)&#xD;
&#xD;
          6. Severe diseases:&#xD;
&#xD;
               1. Cardiovascular system:Diagnosed cardia insufficiency (New York Health Association&#xD;
                  [NYHA] Ⅲ level and higher);Hypertrophic obstructive cardiomyopathy&#xD;
                  (HOCM);Clinical significantly Valvular Disease of the Heart (VDH);Acute coronary&#xD;
                  syndrome or coronary artery interventional therapy or coronary artery bypass&#xD;
                  graft within three months;Severe arrhythmia such as atrial flutter, atrial&#xD;
                  fibrillation, atrioventricular block above Ⅱlevel, et al;&#xD;
&#xD;
               2. Alimentary system:Active virus hepatitis;Any of alanine aminotransferase (ALT),&#xD;
                  aspartate aminotransferase (AST), galactosylhydroxylysyl glucosyltransferase&#xD;
                  (GGT), alkaline phosphatase (ALP), total bilirubin (TBIL), Direct Bilirubin (DB)&#xD;
                  was above 2 times of it's normal value upper limit, albumin (ALB) greater than 30&#xD;
                  g/L;Stomach bulk resect and gastrojejunostomy;Stomach intestine malabsorption;&#xD;
&#xD;
               3. Urinary system:Serum creatinine greater than or equal to 200 mmol/L;Diagnosed&#xD;
                  stenosis of renal artery, solitary kidney;Renal transplantation;&#xD;
&#xD;
               4. Endocrine system:Type 1 diabetes mellitus or uncontrolled type 2 diabetes&#xD;
                  mellitus (fasting glucose greater than or equal to 11.1 mmol/L);Diagnosed and&#xD;
                  uncontrolled hyperthyrosis;&#xD;
&#xD;
               5. Respiratory system:Pulmonary Heart Disease;Chronic Obstructive Pulmonary&#xD;
                  Disease(COPD);&#xD;
&#xD;
               6. Neuropsychiatric system:Transient Ischemia Attach (TIA) or stroke within 3&#xD;
                  months;Severe peripheral nerve or vegetative nerve functional disturbance; Psyche&#xD;
                  or nervous system dysfunction;Drugs or alcohol dependence;&#xD;
&#xD;
               7. Others:Malignant tumor, malnutrition, haematogenesis dysfunction, et al;&#xD;
&#xD;
          7. Obviously abnormal laboratory examination or signs;&#xD;
&#xD;
          8. Taking other antihypertensive drugs and unwilling to stop;&#xD;
&#xD;
          9. Taking folic acid or other Vitamin B groups and unwilling to stop;&#xD;
&#xD;
         10. Ever to participant in any drug trial not yet approved within 4 weeks before the first&#xD;
             visit.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wang Jiguang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital, Shanghai Jiao Tong University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical College</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wang Zhirong, MD</last_name>
      <phone>86-0516-85802111</phone>
      <email>xzzrw@163.com</email>
    </contact>
    <investigator>
      <last_name>Wang Zhirong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng Xiaoshu, MD</last_name>
      <phone>86-791-6268844</phone>
      <email>xiaoshumenfan@126.com</email>
    </contact>
    <investigator>
      <last_name>Cheng Xiaoshu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiao Tong Univesity</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang Jiguang, MD</last_name>
      <phone>86-021-64370045</phone>
      <email>jiguangw@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Wang Jiguang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>September 30, 2013</study_first_submitted>
  <study_first_submitted_qc>September 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>September 30, 2013</last_update_submitted>
  <last_update_submitted_qc>September 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amlodipine</keyword>
  <keyword>Folic Acid</keyword>
  <keyword>Homocysteine</keyword>
  <keyword>Blood Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

